This post was originally published on this site Using Keytruda (pembrolizumab) in combination with chemotherapy increased the percentage of patients showing no signs of breast cancer after completing a course of neoadjuvant therapy — treatment to shrink a tumor — and surgery, interim analysis of a Phase 3 trial shows. This marks the first time…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Jakafi Shows Promise for Treatment of Cutaneous Sarcoidosis, Report Says
This post was originally published on this site Using Jakafi (ruxolitinib) to treat a woman with polycythemia vera (PV; a blood cancer) led to complete resolution of her cutaneous sarcoidosis, and to mild reduction of her lung nodules, according to a case report. The findings suggest a new therapeutic strategy, especially for patients with cutaneous sarcoidosis,…
Phase 1 Trial of Betalutin, a Radioimmunotherapy, in Advanced DLBCL Now Fully Enrolled
This post was originally published on this site The Phase 1 trial evaluating Betalutin — an investigational tumor-targeting antibody labeled with a type of radiation — in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is now fully enrolled, its developer, Nordic Nanovector, announced. The ongoing LYMRIT 37-05 trial (NCT02658968) includes 18 patients who are…
‘Off-the-shelf’ CAR T-Cell Therapy Moving Toward 1st Clinical Trial with Takeda
This post was originally published on this site A new chimeric antigen receptor (CAR) T-cell therapy derived from induced pluripotent stem cells (iPSCs) has been transferred to Takeda from the Center for iPS Cell Research and Application (CiRA) at Kyoto University to prepare for clinical testing. Under the terms of the collaboration, Takeda shall retain the…
Xtandi Delays Disease Worsening in Metastatic Hormone-sensitive Prostate Cancer, Study Says
This post was originally published on this site Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how spread the disease is, a Phase 3 clinical trial shows. It also improved several other patient outcomes, extending the time to a new cancer…
$566K Grant Will Support Research on Use of Contraceptive Pill to Prevent Ovarian Cancer
This post was originally published on this site A $566,000 grant, awarded via the Ovarian Cancer Research Foundation, will support research in Australia that aims to establish the use of contraceptive pills as an effective strategy for preventing ovarian cancer. The three-year grant will enable researchers to continue exploring how changes in female reproductive hormones…
First Patient Dosed in Phase 1 Trial of Antibody for Advanced Multiple Myeloma, Teneobio Announces
This post was originally published on this site A Phase 1 trial evaluating Teneobio’s bispecific antibody TNB-383B as a treatment for multiple myeloma has started dosing patients. This safety and tolerability trial is recruiting people with advanced disease, who received at least three prior lines of therapy. The open-label study (NCT03933735) will first test increasing…
First Generic Version of Navelbine Launched in Europe for Breast, Lung Cancers
This post was originally published on this site Lotus Pharmaceuticals has launched the first generic version of Pierre Fabre’s Navelbine (vinorelbine) in soft capsule form in Europe for the treatment of advanced breast cancer and advanced non-small-cell lung cancer, the company has announced. Vinorelbine soft capsules are now being marketed across Europe, including in France,…
Gray Foundation Awards $3.75M to Study of BRCA Mutations in Ovarian and Other Cancers
This post was originally published on this site The Gray Foundation awarded a $3.75 million grant to a researcher team to study how BRCA1 or BRCA2 mutations, along with other genetic anomalies, increase the risk of breast, ovarian, and other cancers. The “team science grant” will fund the research for four years. The project is…
Tally of Risk Factors Can Identify Myeloma Patients at Risk of Deep-vein Blood Clots, Study Suggests
This post was originally published on this site A simple score of risk factors could help alert doctors to a likelihood of dangerous blood clots, called venous thromboembolism, forming as a side effect of immunomodulatory therapies (IMiD) for multiple myeloma. Researchers established the set of factors — based on a person’s age, race, and medical…
Oklahoma Ranks Lowest on Programs Key to Rare Diseases on NORD’s 2019 State Report Card
This post was originally published on this site Oklahoma suffers more tornadoes than any other state, has the highest per-capita rate of women in U.S. prisons, ranks second in the number of teen births per 100,000 teenage girls, and has the nation’s third-highest rate of uninsured residents — with 13.9% of all Oklahomans lacking health…
Rare Disease Groups Seek Public Support to Renew Newborn Screening Act in Senate
This post was originally published on this site Screening newborns for genetic diseases with treatments that can prevent crippling or deadly progression, especially for rare disorders, has a ways to go in the United States. No state today tests for all 35 disorders recommended under a federal screening panel, and even in those that come…